Skip to content

Clinical Evaluation of Chyawanprash for the prevention of COVID-19 among Health Care Personnel .

Clinical Evaluation of Chyawanprash for the prevention of COVID-19 among Health Care Personnel â?? An open label, prospective Randomized controlled study

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/09/027974
Enrollment
200
Registered
2020-09-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Standard Preventive Regimen plus Ayurveda Rasayana (Chyawanprash): Standard Preventive Regimen for healthcare workers(Standard precaution, Hand hygiene, Personal protective equipment ,

Sponsors

Central Council for Research in Ayurvedic Sciences CCRAS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All healthcare professionals and staff of age group between 25 to 60 years willing to participate, negative for SARS- Cov-2 at screening,(tested by rt-PCR), at KGMU , without co-morbid condition with exposure/chance of exposure to COVID 19 positive cases. Who are willing to provide signed informed consent. High Risk Group- It includes doctors, nursing staff and other paramedical staff like attendant who are directly looking after and examining COVID patients. Low risk- other faculty members who are present in the institute but not visiting corona ward.

Exclusion criteria

Exclusion criteria: Pregnant and lactating females. Immune compromised and co morbid condition cases. Laboratory confirmed COVID-19 with or without symptoms Known allergy to any of the medications used in this trial. Not willing to participate in the study. Subjects who are taking any other medicine as prophylaxis such as HCQ.

Design outcomes

Primary

MeasureTime frame
Percentage of participants with SARS- Cov-2 positivity as estimated by RT-PCR of nasopharyngeal swab / Chemiluminiscence assay after 1 month of consuming Chyawanprash.Timepoint: Baseline, 7th day,15th day,and 30th day

Secondary

MeasureTime frame
Safety profile of the intervention as estimated by LFT, KFT and other haematological & biochemical investigations. Presence or absence of AE/ADR. Number of participants who developed any infective diseases during the trial period (bacterial /viral/ fungal / etc.) and percentage of participants with Upper respiratory tract illness during the period. Immune and inflammatory markers (IgG, IgM, IgE, Hs-CRP TNF - α,IL6, IL10) baseline and end of treatment. Timepoint: Baseline ,on 7th day,on 15th day,and completion of study 30th day.

Countries

India

Contacts

Public ContactDr Satyendra Kumar Sonkar

KGMU ,Lucknow

satyendra.sonkar@gmail.com9307288648

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026